Products - Skin cancer | Topic | NICE

Showing 10 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Melanoma (metastatic) - talimogene laherparepvec [ID508]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
28 September 2016
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
21 April 2021
Suspected Cancer: recognition and referral (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
15 April 2026
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
10 July 2026
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
10 February 2027
Cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6659]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
24 March 2027
Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6473]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over [ID6475]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Imsamotide with etimumotide and pembrolizumab for untreated unresectable or metastatic melanoma in people 12 years and over [TSID12279]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC